Home › NDC Lookup › Ingredients › L- Arginine › 85551-0123-30
Non-proprietary name L- Arginine 100 mg/mL Injection, 30 mL — NDC 85551-0123-30 package photo

Non-proprietary name L- Arginine 100 mg/mL Injection, 30 mL

by Xseer Pharmaceuticals · 30 mL in 1 VIAL, GLASS (85551-123-30)
NDC 85551-0123-30
🏷️ FDA NDC (as labeled) 85551-123-30 billing pads the product segment with a zero
Rx only On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 85551-123-30
Product NDC 85551-123
11-digit billing NDC 85551012330
UNII F7LTH1E20Y
SPL Set ID 3c6c0ac6-0d2a-b865-e063-6294a90aa3d2
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2026-06-01
Route INTRAMUSCULAR, INTRAVENOUS
Dosage form INJECTION
Substance ARGININE HYDROCHLORIDE
Why two NDCs? The FDA registers this code as 85551-123-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 85551-0123-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerXseer Pharmaceuticals
Labeler code85551
First marketedJun 2026
Product typeHuman Prescription Drug
Portfolio4 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

🧪 What is this product?

This is an unapproved injectable medication containing L-arginine (as arginine hydrochloride) at a concentration of 100 mg per milliliter, given by intramuscular or intravenous injection. L-arginine is an amino acid commonly used in medical settings to support various physiological functions, including immune function and wound healing. This product is marketed without an approved FDA application and is not FDA-approved.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII LKG8494WBH
    Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Non-proprietary name 100 mg/mLthis 85551-0123-30 Xseer 30 ml — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2026
On the market since
Jun 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for L-Carnitine — the ingredient across all brands.

Top reported reactions

Vomiting1

Reporter sex

1 reports
Female · 100%
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
85551-0123-30 You're viewing this 30 mL in 1 VIAL, GLASS (85551-123-30) 2026-06-01 Active

🧭 About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 85551-123-30, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 85551-0123-30, written without dashes as 85551012330. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 85551-0123-30, the first segment (85551) is the labeler code FDA assigned to Xseer Pharmaceuticals; the middle segment (0123) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (30) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Xseer Pharmaceuticals. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Xseer Pharmaceuticals is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 📦 Storage and Handling 📋 Description
💊 Dosage Forms and Strengths 38 words ▾

Dosage Forms and Strengts L-Arginine HCl Injection is supplied as a sterile, nonpyrogenic injectable solution containing 100 mg/mL of L-Arginine Hydrochloride in a multiple-dose vial for intravenous administration. Strength: 100 mg/mL Container Closure: 30 mL multiple-dose amber vial.

⛔ Contraindications 91 words ▾

Contraindications L-Arginine HCl Injection is contraindicated in: Patients with known hypersensitivity to L-Arginine, benzyl alcohol, or any component of the formulation. Neonates, premature infants, or low birth weight infants due to the risk of benzyl alcohol toxicity (“gasping syndrome”). Patients with severe metabolic acidosis or conditions where administration of hypertonic solutions may worsen fluid or electrolyte imbalance.

Patients with severe renal impairment or anuria unless clinically justified and closely monitored by a healthcare professional. Patients with hyperchloremic acidosis or known disorders of amino acid metabolism where L-Arginine administration may be inappropriate.

⚠️ Warnings and Cautions 181 words ▾

Warnings and Precautions For intravenous administration only under the supervision of a licensed healthcare professional. This product is a hypertonic solution and should be administered cautiously to minimize the risk of vein irritation, phlebitis, or infusion-related reactions. Use with caution in patients with renal impairment, hepatic impairment, electrolyte imbalance, or acid-base disorders, as L-Arginine may affect metabolic and electrolyte status.

Monitor patients for signs of hypersensitivity reactions, including rash, dyspnea, hypotension, or anaphylactoid reactions. Discontinue administration if a serious reaction occurs. Contains benzyl alcohol 2% as a preservative.

Benzyl alcohol has been associated with serious adverse reactions, including fatal “gasping syndrome,” in neonates and premature infants. Use caution in patients with cardiovascular disease or compromised fluid balance, as intravenous administration may contribute to circulatory overload in susceptible individuals. Rapid or excessive administration may increase the risk of nausea, vomiting, flushing, headache, or hypotension.

Protect from light and from deep freezing. Do not use if the solution is discolored, cloudy, or contains particulate matter. Use aseptic technique when entering the multiple-dose vial.

Discard unused portion according to institutional policy and applicable regulations.

📦 Storage and Handling 98 words ▾

Storage and Handling Store at USP Controlled Room Temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F). Protect from light and from deep freezing. Do not freeze.

Inspect visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not use if the solution is cloudy, discolored, or contains visible particles. This product is supplied as a sterile multiple-dose vial for intravenous administration.

Use aseptic technique when entering the vial. Discard unused portion in accordance with institutional procedures and applicable regulations. Keep out of reach of children.

📋 Description 117 words ▾

Description L-Arginine HCl Injection is a sterile, nonpyrogenic, hypertonic injectable solution containing 100 mg/mL of L-Arginine Hydrochloride in Sterile Water for Injection. The formulation contains benzyl alcohol 2% as a preservative, with pH adjusted to 5.0–6.5 using Hydrochloric Acid and/or Sodium Hydroxide. Each mL contains: L-Arginine HCl 100 mg Benzyl Alcohol 2% Sterile Water for Injection q.s.

The solution is supplied as a multiple-dose vial for intravenous administration by a licensed healthcare professional. The calculated osmolarity is approximately 1148 mOsm/L. L-Arginine is an amino acid involved in multiple metabolic and physiologic pathways, including nitric oxide synthesis and nitrogen metabolism.

The product is compounded by Xseer Pharmaceuticals as a sterile injectable preparation for office or clinical use only.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 85551-0122-30 · Xseer 85551-0125-30 · Xseer →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.